DEGARELIX | DEGARELIX | ATC L02BX02
ANTINEOPLASTIC PROSTATE CANCER GONADOTROPIN-RELEASING HORMONE (GNRH) ANTAGONIST IT BINDS REVERSIBLY TO THE PITUITARY GNRH RECEPTORS THEREBY REDUCING THE RELEASE OF GONADOTROPINS AND CONSEQUENTLY TESTOSTERONE | SUBCUTANEOUS | Cmax 16 NANOMOLAR (240 MILLIGRAM) VD 1000 LITER PPB 90 PERCENT Cl 9 LITER / HOUR HT 1272 HOUR | GONADOTROPIN-RELEASING HORMONE | Gonadotropin-releasing hormone receptor UNIPROT P30968 GNRHR more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |